Abstract 246P
Background
Despite various awareness programmes and strict regulations for consumption of tobacco and alcohol, the incidence of oral cavity cancer is increasing in low and middle income countries. We have reported here clinico-epidemiological profile of 343 oral cavity cancer patients. Although, treatment guidelines exist, treatment failure is seen in more than 50% of patients.
Methods
We retrospectively analysed the data of 343 oral cavity cancer patients who reported to our department during 2010-2015. Detailed history and clinical examination followed by requisite investigations were done and treatment was given as per the existent guidelines.
Results
Out of 343 patients, 283 (82.5%) were males while 60 (17.4%) were females with a male: female ratio of 4.7:1. The mean and median age for the cohort was 46.2 yrs and 45 yrs, respectively. More patients presented in the age group of 31-40 yrs (29.4%) and 41-50 yrs (27.4%). The youngest patient was 21 yrs while the oldest was 85 yrs. Tongue was the most common site of involvement followed by buccal mucosa. Histopathologically, tumours with moderate differentiation were most frequent followed by well differentiated. Approximately, 60% patients underwent surgery with or without adjuvant radiation. Remaining 40% cases, for whom surgery could not be done, received definitive radiation. Overall, however, 40% of cases had treatment failure despite aggressive multimodality treatment with local recurrence observed in more than half. Locoregional recurrence occurred in 19.1% while disease metastasized to distant areas in 8.8% cases.
Conclusions
Our study provided a clinico-epidemiological profile and failure rates of patients having oral cavity cancers in North India. We have tried to study various risk factors associated with the disease. Significant number of patients presents very late in our setting and so failure rates are unacceptably high. Hence, there is a need to study various therapies for effective management without adding any significant financial burden on patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
154P - Can urine cytology predict variants of bladder cancer?
Presenter: Hikaru Mikami
Session: Poster viewing 03
155P - Search for circulating tumor cells in patients with urothelial cancer
Presenter: Irina Kruglova
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03